Anemia and Red Blood Cells Transfusion in Oncological Surgery

Surgery Clinical Trial

— IMPACT  

Official title:

Impact of Perioperative Anemia and Red Blood Cells Transfusion on Post-operative Complications After Oncological Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04101240
• Other study ID #: IMPACT (29BRC19.0013)
• Status: Recruiting
• Start date: February 7, 2019
• Est. completion date: November 30, 2019

Study information

• Verified date: September 2019
• Source: University Hospital, Brest
• Contact: Cécile AUBRON, PU PH
• Phone: +33298347181
• Email: cecile.aubron[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Oncologic patients experience anemia and anemia is associated with poor prognosis. Transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality.

Description:

Between 36 and 75% of oncologic patients experience anemia and anemia is associated with poor prognosis. Up to 40% of surgical oncologic patients receive red blood cells (RBC). However, transfusion is associated with adverse events, and equipoise remains on the optimal transfusion strategy in oncologic patients in surgical setting. The primary objective of this study is to determine the impact of anemia and red blood cells (RBC) transfusion on post-operative complications and mortality. This is a retrospective, single center study. All adults admitted to the intensive care unit (ICU) after oncologic surgery within the study period are eligible.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: November 30, 2019
• Est. primary completion date: November 30, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Surgery for cancer

• Admission to intensive care

Exclusion Criteria:

• no consent

Related Conditions & MeSH terms

• Anemia
• Oncology
• Surgery

Locations

Country	Name	City	State
France	CHRU de Brest, hôpital de la Cavale Blanche	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of mortality or any respiratory, cardiac, renal, thromboembolic, infectious and/or hemorrhagic post operative complications	mortality or any respiratory, cardiac, renal, thromboembolic, infectious and/or hemorrhagic post operative complications	30 DAYS (hospital discharge)